BEGIN:VCALENDAR PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN VERSION:2.0 METHOD:PUBLISH X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VTIMEZONE TZID:GMT Standard Time BEGIN:STANDARD DTSTART:16011028T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZOFFSETFROM:+0100 TZOFFSETTO:-0000 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010325T010000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZOFFSETFROM:-0000 TZOFFSETTO:+0100 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT CATEGORIES:Stage 3 CLASS:PUBLIC CREATED:20250512T125545Z DESCRIPTION:Presentation:\nThe ACE Pico Protocol: A Breakthrough in Multi-d osing Cellular Therapy for Pharmaceutical and Biotech Application\n \nThur sday 15.30 to 15.50\, Stage 3\n \nSpeaker: Dr. Alaa Abdelkarim - Member of the Royal Society of Chemistry and founder of ACE Cells Lab Limited\n \nA bout this presentation\nThe ACE Pico Protocol introduces a transformative platform in regenerative medicine and pharmaceutical biotechnology by conv erting stem cells into polydisperse nanoscale fragments (5–20 nm) throug h a cold (<10°C)\, mechanical dissociation process. This protocol enables non-invasive\, multiple-doses sublingual administration of a “whole cel l” payload—including membranes\, organelles\, proteins\, and nucleic a cids—addressing longstanding challenges of multi-dosing\, immune respons e\, and patient compliance in cellular therapies.\n \nComprehensive analys is using electron microscopy (EM) and UV-Vis spectrophotometry confirmed t he bioactive integrity of the processed materials\, with strong absorbance peaks for proteins and pigments\, and optimal particle sizes for mucosal uptake. In animal models\, high-dose sublingual administration (2000 mg/kg ) revealed no toxicity\, while plasma protein studies across five administ ration routes demonstrated the highest systemic protein increase via the s ublingual route (0.66 g/dL\, p<0.01). These findings underscore superior a bsorption\, therapeutic potential\, and safety.\n \nCompared to exosomes\, peptides\, or liposomal delivery systems\, the ACE Pico Protocol offers b roader therapeutic payloads\, reduced degradation risk\, and enhanced stab ility\, making it a compelling platform for next-generation pharmaceutical formulations and biologic delivery systems.\n \nDr. Alaa Abdelkarim - Che mical UK Expo \n DTEND;TZID="GMT Standard Time":20250522T155000 DTSTAMP:20250509T153715Z DTSTART;TZID="GMT Standard Time":20250522T153000 LAST-MODIFIED:20250512T125545Z LOCATION:Stage 3 PRIORITY:5 SEQUENCE:0 SUMMARY;LANGUAGE=en-gb:Presentation: The ACE Pico Protocol: A Breakthrough in Multi-dosing Cellular Therapy for Pharmaceutical and Biotech Applicatio n TRANSP:OPAQUE UID:040000008200E00074C5B7101A82E00800000000B0B65A7200C1DB01000000000000000 0100000002881CA8D96618C46BAA9ECCCA45A4D98 X-ALT-DESC;FMTTYPE=text/html:\n\n< /xml>

Presentation:< /p>

T he ACE Pico Protocol: A Breakthrough in Multi-dosing Cellular Therapy for Pharmaceutical and Biotech Application

\;

Thursday 15.30 to 15.50\, Stage 3

\;

Speaker: Dr. Alaa Abdelkarim - Member of the Royal Society of Chemi stry and founder of ACE Cells Lab Limited

\;

About this presentation

The ACE Pico Protocol int roduces a transformative platform in regenerative medicine and pharmaceuti cal biotechnology by converting stem cells into polydisperse nanoscale fra gments (5–20 nm) through a cold (<\;10°C)\, mechanical dissociation p rocess. This protocol enables non-invasive\, multiple-doses sublingual adm inistration of a “whole cell” payload—including membranes\, organell es\, proteins\, and nucleic acids—addressing longstanding challenges of multi-dosing\, immune response\, and patient compliance in cellular therap ies.

\;

Comprehensive analysis using elec tron microscopy (EM) and UV-Vis spectrophotometry confirmed the bioactive integrity of the processed materials\, with stron g absorbance peaks for proteins and pigments\, and optimal particle sizes for mucosal uptake. In animal models\, high-dose sublingual administration (2000 mg/kg) revealed no toxicity\, while plasma protein studies across f ive administration routes demonstrated the highest systemic protein increa se via the sublingual route (0.66 g/dL\, p<\;0.01). These findings under score superior absorption\, therapeutic potential\, and safety.

\;

Compared to exosomes\, peptides\, or liposomal d elivery systems\, the ACE Pico Protocol offers broader therapeutic payload s\, reduced degradation risk\, and enhanced stability\, making it a compel ling platform for next-generation pharmaceutical formulations and biologic delivery systems.

\;

< p class=MsoNormal>D r. Alaa Abdelkarim - Chemical UK Expo

X-MICROSOFT-CDO-BUSYSTATUS:BUSY X-MICROSOFT-CDO-IMPORTANCE:1 X-MICROSOFT-DISALLOW-COUNTER:FALSE X-MS-OLK-AUTOFILLLOCATION:FALSE X-MS-OLK-AUTOSTARTCHECK:FALSE X-MS-OLK-CONFTYPE:0 END:VEVENT END:VCALENDAR